Products Test - Bimatoprost 0.01% Ophthalmic Solution + Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)
Test - Bimatoprost 0.01% Ophthalmic Solution + Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution) Phase 3 Completed 📈 Rising Oct 2, 2021 → Aug 11, 2022
About Test - Bimatoprost 0.01% Ophthalmic Solution + Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution) Test - Bimatoprost 0.01% Ophthalmic Solution + Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution) is a phase 3 stage product being developed by Mankind Pharma for Glaucoma, Open-Angle. The current trial status is completed. This product is registered under clinical trial identifier NCT04890106. Target conditions include Glaucoma, Open-Angle.
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT04890106 Phase 3 Completed Oct 2, 2021 Aug 11, 2022 Glaucoma, Open-Angle
Product Company Stage Hype Score Latanoprost plus adjunctive glaucoma medication Sight Sciences Approved SBI-100 Ophthalmic Emulsion, 0.5% + SBI-100 Ophthalmic Emulsion, 1.0% + SBI-100 Ophthalmic Emulsion, Placebo Skye Bioscience Phase 2 SDP-133 + Lumigan Sun Pharmaceutical Phase 3 Brinzolamide ophthalmic suspension + Azopt® Sun Pharmaceutical Phase 3 Eybelis ophthalmic solution 0.002% Santen Pharmaceutical Approved STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5% Santen Pharmaceutical Phase 3 Latanoprost + tafluprost Santen Pharmaceutical Pre-clinical DE-117B Eye Drops + Latanoprost Santen Pharmaceutical Phase 3 DE-104 ophthalmic solution + DE-104 vehicle Santen Pharmaceutical Phase 2 DE-111 ophthalmic solution + Tafluprost ophthalmic solution 0.0015% + Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5% Santen Pharmaceutical Phase 3 DE-111 ophthalmic solution Santen Pharmaceutical Phase 3 DE-111 ophthalmic solution + Timolol ophthalmic solution 0.5% + Placebo ophthalmic solution Santen Pharmaceutical Phase 3 DE-104 ophthalmic solution, low concentration + DE-104 ophthalmic solution, medium concentration + DE-104 ophthalmic solution, high concentration + DE-104 vehicle Santen Pharmaceutical Phase 2 DE-117 ophthalmic solution + Latanoprost ophthalmic solution 0.005% Santen Pharmaceutical Phase 3 STN1012600 ophthalmic solution 0.002% + Latanoprost ophthalmic solution 0.005% Santen Pharmaceutical Phase 3 DE-117 + Latanoprost ophthalmic solution Santen Pharmaceutical Phase 3 DE-117 ophthalmic solution + Timolol ophthalmic solution Santen Pharmaceutical Phase 3 A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL + A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mL Santen Pharmaceutical Phase 3 Placebo ophthalmic solution + DE-117 ophthalmic solution low + DE-117 ophthalmic solution high + Latanoprost ophthalmic solution 0.005% Santen Pharmaceutical Phase 2/3 Bimatoprost SR AbbVie Phase 3
Other Products from Mankind Pharma